[Skip To Content]
[Website of the National Cancer Institute's Technology Transfer Center. Partnering with Industry for Improved Public Health.]
  • Home
  • Collaborative Opportunities
  • Standard Forms and Agreements
  • Technology Transfer Training
  • Resources
  • Intellectual Property

Anakin Protein as a Prognostic Tool for Diagnosing Breast Cancer Outcome

Available for collaborative research toward commercial development and/or exclusive and non-exclusive licensing:
  • Method of diagnosis for early metastasis and therapeutic inhibition of metastasis.
  • Nucleic acid sequence of Anakin protein, an extracellular matrix (ECM) modifier gene.
  • SiRNA sequences that inhibit Anakin expression as therapeutics. Purified antibodies that recognize Anakin protein as a research reagent and in diagnostics related products.
Recent evidence suggests that metastatic disease can be an early event and in majority of patients metastasis starts by the time the disease is diagnosed. Thus there is a need for methods of characterizing the early metastatic process for better treatment of cancer.

This invention provides methods of characterizing the metastatic capacity of a tumor as well as inhibiting metastasis of a cancer cell. More specifically, this invention discloses an extracellular matrix (ECM) modifier protein named Anakin, detection of the Anakin protein as a marker for metastatic disease and use of Anakin as potential therapeutic target.

Development Status:
 Pre-clinical

Contact Information:
John D. Hewes, Ph.D., NCI Technology Transfer Center
Phone: 301-435-3121
E-mail: Hewesj@mail.nih.gov

Reference:  #431 RW

Updated 10/24/2007

This opportunity is also listed under the following categories:

E-MAIL SERVICE

TTC maintains an e-mail service to notify you of new Collaborative Opportunities. If you would like to receive these emails, please sign up below. If you'd like to unsubscribe you can use this form as well.

Page Last Updated: 12-17-2008